¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2021 Semi-Annual Meeting : 2021-05-15

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2021 Semi-Annual Meeting : 2021-05-15
±³À°ÀÏÀÚ : 2021-05-15
±³À°Àå¼Ò : ºí·ëºñ½ºÅ¸ ¾çÆò  
±³À°ÁÖÁ¦ : KGOG 2021 Semi-Annual Meeting
ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸  
´ã´çÀÚ : ±èÀμ÷
¿¬¶ôó : 02-512-5444  
À̸ÞÀÏ : koreagynonco@hanmail.net      
±³À°Á¾·ù : »êºÎÀΰú      
Âü¼®¿¹»óÀοø : 99¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : °æ±âµµ
±³À°½Ã°£ : 8 ½Ã°£ 56ºÐ  
¼¼ºÎ¼ö°­·á : 50,000¿ø      
ºñ°í       

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:00~08:15 Lesson model society NRG corpus: What is missing in KGOG?  Matthew A. Powell(NRG Uterine Corpus Committee Chair) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:15~08:30 Reasonable choice of target treatment among HER2(+) uterine cancer patients  Amanda Nickles Fader(Johns Hopkins Hospital) 
Åä·Ð 05-15 ±×·£µåº¼·ë 08:30~08:36 Discussion  () 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:36~08:39 Review of ongoing study- KGOG 2020: EM cancer, Fertility sparing high dose oral progestin ¿Ü  ¹ÚÁ¤¿­(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:39~08:42 Review of ongoing study-KGOG 2021 : TREE PRO  ±è±âµ¿(ºÐ´ç¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:42~08:45 Review of ongoing study-KGOG 2022 (NRG-GY018)  ±è¹ýÁ¾(¿øÀڷº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:45~08:48 Review of ongoing study-KGOG 2023  À̹æÇö(ÀÎÇϴ뺴¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:48~08:51 Review of ongoing study-KGOG 2024 : Phase II CR-GTP, pembroizumab  ÃÖ¹Îö(ºÐ´çÂ÷º´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:51~08:54 Review of ongoing study-KGOG 2025 (AtEND)  ÀÌö¹Î(ÀÏ»êÂ÷º´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:54~08:57 Review of ongoing study-KGOG 2026: RACHEL PRO  ±è±âµ¿(ºÐ´ç¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:57~09:00 Review of ongoing study-KGOG 2027 (NRG-GY020)  ¹ÚÁ¤¿­(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 09:00~09:03 Review of ongoing study-KGOG 2028 : Radiation Oncology & GYN oncology patterns of survey  ±è¹Î±Ô(â¿ø»ï¼ºº´¿ø) 
Åä·Ð 05-15 ±×·£µåº¼·ë 09:03~09:08 Discussion  () 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 09:08~09:18 Proposal of new concepts- A. Sentinel lymph node (SNL) mapping for endometrial cancer  ¹ÚÁ¤¿­(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 09:18~09:28 Proposal of new concepts- Endometrial cancer screening of hysteroscopy with dye (Chromo- Hysteroscopy) in high-risk population (HysteroLynch )  ±è¹Î±Ô(â¿ø»ï¼ºº´¿ø) 
±âŸ 05-15 ±×·£µåº¼·ë 09:28~09:30 Closing  () 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 10:30~10:33 Cervix-Intorudction  À̱ÙÈ£(¼­¿ï¼º¸ðº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 10:33~11:03 Review of ongoing study-KGOG 1028, 1036, 1037  Á¤¿ë¿í(°­³²Â÷º´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 11:03~12:13 Proposal of new concepts A. Comparison of adjuvant radiotherapy versus observation in &quotintermediate risk" early cervical cancer patients after radical hysterectomy: Propensity score matching study  ½É½ÂÇõ(°Ç±¹´ëº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 11:13~11:23 Proposal of new concepts Prediction model for survival and recurrence in early-stage cervical cancer patients with radical trachelectomy: A multicencer cohort study  ±è´ë¿¬(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 11:23~11:33 Proposal of new concepts DEBULK- Therapeutic effect of surgical debulking of metastatic LNs in cervical cancer stage IIIC before CCRT  ³ëÁÖ¿ø(ÀÏ»êÂ÷º´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 11:33~11:43 Proposal of new concepts Real world data of sentinel lymph node dissection in gynecologic cancer  ¼ÛÈñ°æ(¼­¿ï¼º¸ðº´¿ø) 
±âŸ 05-15 ±×·£µåº¼·ë 11:43~11:45 Closing  ±è»ó¿î(¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 13:00~13:25 Niraparib in patients with newly diagnonsed advanced ovarian cancer : PRIMA trial  ±èÈñ½Â(¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 13:25~13:50 Updated data of niraparib in Aasian patient  ¼ÛÇϳª(°æ»ó´ëº´¿ø) 
Åä·Ð 05-15 ±×·£µåº¼·ë 13:50~14:00 Discussion  () 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:00~14:08 Ovary-Introduction  ÃÖÇöÁø(Á߾Ӵ뺴¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:08~14:13 Study Review of OV TSC-KGOG 3035(JGOG3020)  À̼ºÁ¾(¼­¿ï¼º¸ðº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:13~14:18 Study Review of OV TSC-KGOG 3039(SUNNY): Sunny and Trust  ±èÀç¿ø(¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:18~14:23 Study Review of OV TSC-KGOG 3042 IDSHIPEC: Current status of HIPEC in the GYN ONC community  Àå¼®ÁØ(¾ÆÁִ뺴¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:23~14:38 Study Review of OV TSC-KGOG 3045 AMBITION/3025 TRU-D : &quotFrom small Phase to pivotal study"  ÀÌÁ¤À±(¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:38~14:43 Study Review of OV TSC-KGOG 3047 somatic mutational landscape of epithelial ovarian carcinoma and its clinical implications targeted next-generation sequencing: A multi-center study  ÀÌÁ¤¿ø(»ï¼º¼­¿ïº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:43~14:48 Study Review of OV TSC-KGOG 3048: Progress of KGOG 3048  ÃÖ¹Îö(ºÐ´çÂ÷º´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:48~15:53 Study Review of OV TSC-KGOG 3049  À̹æÇö(ÀÎÇϴ뺴¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:53~14:58 Study Review of OV TSC-KGOG 3051(NRG-GY019): Management of low grade serous ovarian cancer  ÀÌÀ¯¿µ(»ï¼º¼­¿ïº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:58~15:03 Study Review of OV TSC-KGOG 3053 (NRG-CC008)  ÃÖÇöÁø(Á߾Ӵ뺴¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 15:03~15:08 Study Review of OV TSC-KGOG 3056: A single-arm phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive ovarian cancer patients previously treated with a PAR inhibitor (Nirvana-R)  ÀÌÁ¤À±(¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 15:08~15:18 Proposal of new concepts A. KGOG 3058: Effectiveness and safety of PARP-inhibitor maintenance therapy in recurrent ovarian cancer patients in real world Retrospective cohort study(ESPOIR)  ÃÖÇöÁø(Á߾Ӵ뺴¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 15:18~15:28 Proposal of new concepts-OV 1908: A Phase I Clinical Trial of the Azacitidine(Azalid¢ç) with the Paclitaxel Polymeric Micelle (Genexol¢ç PM) in the treatment of patients with advanced or metastatic ovarian cancer  À̽ÅÈ­(¼­¿ï¾Æ»êº´¿ø) 
±âŸ 05-15 ±×·£µåº¼·ë 15:28~15:30 Closing  °­¼®¹ü(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 16:30~16:55 Clinical development of PARPi in ovarian cancer (past and future) and development of biomarkers of PARPi and HRD pathway  Richard Davidson(UK) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 16:55~17:20 Optimal front-line treatment with precision medicine in advanced ovarian cancer  ÀÌÀ¯¿µ(»ï¼º¼­¿ïº´¿ø) 
Åä·Ð 05-15 ±×·£µåº¼·ë 17:20~17:30 Discussion  () 
±³À°½Ã°£ 05-15 Room B, C-302 È£ 12:00~12:03 Rare tumor-Introduction  ÃÖöÈÆ(»ï¼º¼­¿ïº´¿ø) 
±³À°½Ã°£ 05-15 Room B, C-302 È£ 12:03~12:23 Mucinous carcinoma of GYN origin (intraepithelial mucinous carcinoma of ovary, gastric type cervical adenocarcinoma)  ±è±Ô·¡(¼­¿ï¾Æ»êº´¿ø º´¸®°ú) 
±³À°½Ã°£ 05-15 Room B, C-302 È£ 12:23~12:31 MIS vs. open surgery in rare histology cervical cancer  ±è¼¼ÀÍ(¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 05-15 Room B, C-302 È£ 12:31~12:39 A MRI based machine learning approach for distinguishing uterine sarcoma from leiomyomas  ±èÅÂÈÆ(º¸¶ó¸Åº´¿ø) 
±³À°½Ã°£ 05-15 Room B, C-302 È£ 12:39~12:47 Radical vs. fertility sparing surgery in intraepithelial mucinous carcinoma of ovary  ½É½ÂÇõ(°Ç±¹´ëº´¿ø) 
±âŸ 05-15 Room B, C-302 È£ 12:47~12:49 Closing  ÃÖöÈÆ(»ï¼º¼­¿ïº´¿ø) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2021 Semi-Annual Meeting : 2021-05-15""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2021³â ´ëÇÑ°í°üÀýÇÐȸ Áø·áÁöħ ½ÉÆ÷Áö¿ò : 2021-05-15
´ÙÀ½±Û (¿Â¶óÀÎ) Á¦21ȸ Çѱ¹Æ÷µµ¸·ÇÐȸ ½ÉÆ÷Áö¾ö : 2021-05-15
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
213 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ¾È°ú ±Ý¿ä¼¼¹Ì³ª : 2018-09-07 0 325 2018-07-28
212 °æ±â ¸íÁöº´¿ø The 3nd MYONGJI INTERNATIONAL LIVER SYMPOSIUM : 2018-09-07 0 428 2018-07-28
211 ¼­¿ï 2018³âµµ ´ëÇѺñ¸¸ÇÐȸ ±¹Á¦Çмú´ëȸ(ICOMES 2018) - 09/07 : 2018-09-07 0 495 2018-07-28
210 ¼­¿ï 2018³â ¼­¿ï¾Æ»êº´¿ø ¾Ïº´¿ø ½ÉÆ÷Áö¾ö : 2018-09-07 0 540 2018-07-28
209 ¼­¿ï ´ëÇÑ°áÇÙ¹×È£Èí±âÇÐȸ 2018³â ¹Î°£¡¤°ø°øÇù·Â(PPM) ±¹°¡°áÇÙ°ü¸®»ç¾÷ Æò°¡´ëȸ : 2018-09-07 0 613 2018-07-28
208 ´ë±¸ ±¹¸³ÀÇ·á¿ø °ø°øÀÇ·á Consensus conference(4Â÷: °æ»óÁ¦ÁÖ±Ç) : 2018-09-07 0 624 2018-07-28
207 ¼­¿ï 2018³â ½ÅÁ¾ ¹× »ý¹°Å×·¯°¨¿°º´ ´ëÀÀÀü¹®¿ä¿ø ±³À°[»çÀüµî·Ï Çʼö] : 2018-09-07 0 327 2018-07-28
206 ¼­¿ï °í·Á´ëÇб³¾È¾Ïº´¿ø ÀÏÂ÷ ÀÇ·áÁø°ú ÇÔ²²ÇÏ´Â ½É¹æ¼¼µ¿ÀÇ Ä¡·á : 2018-09-07 0 556 2018-07-28
205 ¼­¿ï ´ëÇÑÀÇ»çÇùȸ [Á¦27±â ÀÇ·áÁ¤Ã¥ÃÖ°íÀ§°úÁ¤] ÀÇ·á»ç°í¿Í Á¶Á¤ ÁßÀç / ¼³¸íÀǹ« : 2018-09-06 0 413 2018-07-28
204 ¼­¿ï 2018³âµµ ´ëÇѺñ¸¸ÇÐȸ ±¹Á¦Çмú´ëȸ(ICOMES 2018) - 09/06 : 2018-09-06 0 377 2018-07-28
203 ¼­¿ï ±¹¸³ÀÇ·á¿ø 2018³â ½ÅÁ¾ ¹× »ý¹°Å×·¯°¨¿°º´ ´ëÀÀÀü¹®¿ä¿ø ±³À°[»çÀüµî·Ï Çʼö] : 2018-09-06 0 540 2018-07-28
202 °æ±â ÇѸ²´ëÇб³¼º½Éº´¿ø 2018 ¾à¹°ÀÌ»ó¹ÝÀÀ ½ÉÆ÷Áö¾ö : 2018-09-05 0 963 2018-07-28
201 ¼­¿ï ±¹¸³ÀÇ·á¿ø 2018³â ½ÅÁ¾ ¹× »ý¹°Å×·¯°¨¿°º´ ´ëÀÀÀü¹®¿ä¿ø ±³À°[»çÀüµî·Ï Çʼö] : 2018-09-05 0 649 2018-07-28
200 °æ±â ºÐ´ç¼­¿ï´ëÇб³º´¿ø »ç½Ã Áø·áÀÇ ÇÔÁ¤À» ÇÇÇØ°¡·Á¸é : 2018-09-04 0 1,077 2018-07-28
199 ¼­¿ï Á¦ÀϺ´¿ø 2018 »ý½Ä¹ß»ýµ¶¼º¿¬±¸ ¹× ¸¶´õ¸®½ºÅ©ÇÁ·Î±×·¥ÀÇ ÃֽŰæÇâ : 2018-09-02 0 728 2018-07-28
1391 | 1392 | 1393 | 1394 | 1395 | 1396 | 1397 | 1398 | 1399 | 1400
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷